Teon Therapeutics
Teon Therapeutics is developing oral small molecule therapies that target unexploited metabolic signaling pathways to restore anti-tumor immunity in patients with solid tumors. By addressing the limitations of current immunotherapy options, Teon aims to improve treatment outcomes and allow patients to spend more time with their loved ones.
- Biotechnology
Funding
Raised to date
$35MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current immunotherapy drugs are only effective in a small percentage of patients with solid tumors. Many patients with cancer undergo lengthy infusions and spend significant time away from their families. There is a need for more accessible and effective cancer treatments that can improve patient outcomes and quality of life.
Solution
Teon Therapeutics is developing oral small molecule therapies designed to restore anti-tumor immunity in patients with solid tumors by targeting unexploited metabolic signaling pathways. Their approach aims to overcome the limitations of existing immunotherapy options by providing a once-daily, oral medication. By targeting these pathways, Teon's therapies reverse immune cell suppression and halt tumor growth, potentially leading to better outcomes and allowing patients to spend more time with their loved ones. The company's pipeline focuses on GPCR-directed therapies with first- and best-in-class candidates in oncology.
Target Audience
The primary target audience includes patients with solid tumors who are not adequately served by current immunotherapy options, as well as the healthcare providers who treat them.
Features
- Oral small molecule therapies for convenient administration
- Targets unexploited metabolic signaling pathways to restore anti-tumor immunity
- GPCR-directed therapies designed to reverse immune cell suppression and halt tumor growth
- Focused clinical-stage pipeline with first- and best-in-class candidates